You are currently viewing Where Is The AI In Biotechnology Market Heading? Size, Trends And Forecast Through 2030
AI In Biotechnology Market Analysis

The Business Research Company’s 2026 market reports combine market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights to deliver research that is more actionable and strategically valuable.

AI In Biotechnology Market Size Review: What Shaped Past Growth And What Will Drive Future Expansion?

The AI in biotechnology market has experienced substantial growth in recent years. Its size is projected to increase from $5.52 billion in 2025 to $6.87 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 24.4%. Historically, this expansion has been driven by increased biological data availability, the early adoption of bioinformatics, rising expenditures in drug development, the demand for quicker diagnostics, and the broadening scope of genomics research.

The AI in biotechnology market is anticipated to experience substantial growth over the next few years. It is projected to expand to $16.32 billion in 2030, growing at a compound annual growth rate (CAGR) of 24.1%. This expansion during the forecast period is primarily driven by advancements in machine learning algorithms, the increasing adoption of precision medicine, rising AI investments in the life sciences sector, the demand for more cost-effective drug development processes, and the integration of AI with laboratory automation. Significant trends expected in this period encompass AI driven drug discovery, predictive genomics analysis, optimized automated clinical trials, AI enabled diagnostics, and data centric personalized medicine.

Access Free Sample Pages From The AI In Biotechnology Market Report 2026:

https://thebusinessresearchcompany.com/sample_request?id=10166696&type=smp&name=AI%20In%20Biotechnology%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Understanding The Main Driver Of The AI In Biotechnology Market

The growing integration of AI is projected to fuel the expansion of the AI in biotechnology market in the coming years. Artificial intelligence (AI) encompasses the imitation of human intelligence functions by machines, particularly computer systems, to execute tasks such as learning, logical deduction, and problem-solving. Its widespread uptake stems from its capacity to boost efficiency, precision, and decision-making across various industries, exemplified by its aptitude for automating intricate data analysis with unwavering accuracy. Within the biotechnology domain, AI contributes significantly by expediting drug discovery, streamlining research workflows, and facilitating sophisticated predictive modeling to achieve enhanced healthcare results. A concrete example of this trend is observed in October 2024, where data from the Department for Science, Innovation & Technology (DSIT), a UK-based government agency, indicated that the increasing embrace of artificial intelligence (AI) in 2023 led to a 17% rise in the number of AI companies (+543), a 34% surge in AI-related revenues (+£3.6 billion), a 29% increase in employment (+14,500), and a nearly 57% jump in gross value added (GVA) (+£2.1 billion) when compared to the 2022 report. Consequently, the heightened integration of AI is undeniably propelling the expansion of the AI in biotechnology market.

AI In Biotechnology Market Segment Mapping For 2026 And Beyond

The AI in biotechnology market covered in this report is segmented –

1) By Component: Software, Hardware, Services

2) By Application: Drug Discovery And Development, Clinical Trials And Optimization, Medical Imaging, Diagnostics, Other Applications

3) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes, Healthcare Providers, Contract Research Organization (CRO) And Contract Development And Manufacturing Organization (CDMO), Other End Users

Subsegments:

1) By Software: AI-Powered Data Analytics Tools, Machine Learning Algorithms, Bioinformatics Software, Drug Discovery Platforms, Clinical Trial Management Software

2) By Hardware: High-Performance Computing (HPC) Systems, AI-Integrated Imaging Devices, Data Storage Solutions, Laboratory Automation Equipment, Wearable Health Monitoring Devices

3) By Services: AI Implementation And Integration Services, Consulting And Training Services, Cloud-Based AI Solutions, Maintenance And Support Services, Custom AI Model Development

What Key Trend Is Expected To Shape The AI In Biotechnology Market Over The Forecast Period?

Leading firms in the AI in biotechnology market are prioritizing the creation of advanced technologies, such as AI-driven antibody discovery platforms, to secure a market advantage. An AI-powered antibody discovery platform is a technology-based system that leverages artificial intelligence for the swift identification and refinement of therapeutic antibodies, thereby facilitating quicker, more economical drug development and enhanced biopharmaceutical outcomes. As an example, AION Labs, a venture studio located in Israel, introduced DenovAI in February 2023; this platform is engineered for the de novo discovery of therapeutic antibodies. This innovative solution integrates machine learning and computational biophysics to pinpoint high-affinity antibody candidates, offering improved precision, greater sequence diversity, and substantially shorter development durations. DenovAI signifies a groundbreaking progression in biotechnology, enabling accelerated and more budget-friendly drug discovery while boosting the likelihood of clinical triumph across a broader range of ailments.

AI In Biotechnology Market Major Players And Industry Competition Overview

Major companies operating in the AI in biotechnology market are Google LLC, Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., International Business Machines Corporation (IBM), Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Novartis AG, Roivant Sciences Ltd., Gilead Sciences Inc., NVIDIA Corporation, Amgen Inc., Novo Nordisk A/S, Merck KGaA, Biogen Inc., CareDx Inc., Clario Inc., BenevolentAI Limited, Recursion Pharmaceuticals Inc., Insilico Medicine Inc., Genesis Therapeutics Inc.

Full AI In Biotechnology Market Report: Market Size, Trends, Segments And Key Players:

https://thebusinessresearchcompany.com/report/ai-in-biotechnology-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

AI In Biotechnology Market Geographic Segmentation: Regions Covered In The Report

North America was the largest region in the AI in biotechnology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the AI in biotechnology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model